Article
Prognosis of EGFR-mutant Lung Adenocarcinoma Patients With Malignant Pleural Effusion Receiving First-line EGFR-TKI Therapy Without Pleurodesis: A Single-institute Retrospective Study.
Anticancer research - 1 Feb 2020
Kashiwabara Kosuke, Fuji Shinji, Tsumura Shinsuke, Sakamoto Kazuhiko
Abstract excerpt
BACKGROUND/AIM: The survival benefit of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy without pleurodesis in EGFR-mutant lung adenocarcinoma patients with malignant pleural effusions (MPE) remains unclear. PATIENTS AND METHODS: We retrospectively evaluated overall survival (OS) among EGFR wild-type lung adenocarcinoma patients with MPE who received chemotherapy with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.